Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Candesartan add-on trial in insulin-resistant obese patients with uncontrolled hypertension
2006-001998-25Phase 4Completed
- Sponsor
- Takeda
- Start
- Jul 2006
- Modality
- Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in hypertension (HTN) comparing Candesartan cilexetil + hydrochlorothiazide add-on with Placebo + hydrochlorothiazide add-on (2 arms). Primary endpoint: Mean reduction in trough seated diastolic blood pressure. Started Jul 2006; status: completed.
02
Drugs
candesartan cilexetilhydrochlorothiazide
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on 2006-001998-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001998-25.